Page 10 - John Tsai News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from John tsai. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In John Tsai Today - Breaking & Trending Today

Novartis' nuclear therapy helps men with prostate cancer live longer - data

3 minute read
The company s logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/File Photo
Men with a deadly form of advanced prostate cancer who failed other treatments survived four months longer after getting an experimental, tumour-targeting radiation therapy from Swiss drugmaker Novartis (NOVN.S), data released on Thursday showed.
The company s Lu-PSMA-617 therapy boosted median overall survival (OS) to 15.3 months in patients with metastatic castration-resistant prostate cancer, according to data released at the 2021 American Society of Clinical Oncology annual meeting.
That compared with 11.3 months for men who got standard care. ....

New York , United States , Memorial Sloan Kettering Cancer Center , Michael Morris , John Tsai , Thomson Reuters Trust Principles , American Society Of Clinical Oncology , Clinical Oncology , Thomson Reuters Trust , M Ez , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , நினைவகம் ஸ்லோன் கெட்டரிங் புற்றுநோய் மையம் , மைக்கேல் மோரிஸ் , ஜான் ட்‌ஸை , தாம்சன் ராய்ட்டர்ஸ் நம்பிக்கை ப்ரிந்ஸிபல்ஸ் , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் , மருத்துவ புற்றுநோயியல் , தாம்சன் ராய்ட்டர்ஸ் நம்பிக்கை ,

Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program | Antibodies

Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program ....

United States , United Kingdom , Lookeren Campagne , Beovu Basel , John Tsai , World Health Organization , Global Head Of Drug Development , Health Qual Life Outcomes , Canadian Drug Expert Committee Recommendation , National Eye Institute , National Health Insurance Pricing , European Society Of Retina Specialists , Canadian Agency For Drugs , Nj Novartis Pharmaceuticals Corporation , Technologies In Health , Lancet Glob Health , United Statesi May , Global Head , Drug Development , Chief Medical Officer , North America , Age Related Macular Degeneration , Retinal Vascular , East Hanover , Pharmaceuticals Corporation , Double Masked Trials ,

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program

NOVARTIS AG CHF0.50(REGD)
Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program
Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program
Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase
1
In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and retinal vascular occlusion versus aflibercept ....

United States , United Kingdom , Isabella Zinck , Rachel Fink , Lookeren Campagne , Thomas Hungerbuehler , Amy Wolf , Samir Shah , Julie Masow , Beovu Basel , Sloan Simpson , John Tsai , Novartis Division Communications , World Health Organization , Global Head Of Drug Development , Novartis External Communications , Health Qual Life Outcomes , Exchange Commission , Canadian Drug Expert Committee Recommendation , National Eye Institute , National Health Insurance Pricing , European Society Of Retina Specialists , Canadian Agency For Drugs , Technologies In Health , Lancet Glob Health , Global Head ,

Novartis Pharma AG: Novartis reports one year results of Phase III MERLIN study evaluating Beovu every four week dosing and provides update on Beovu clinical program

Beovu (brolucizumab) met MERLIN's primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept ....

United States , United Kingdom , Isabella Zinck , Rachel Fink , Lookeren Campagne , Thomas Hungerbuehler , Amy Wolf , Samir Shah , Julie Masow , Beovu Basel , Sloan Simpson , John Tsai , Novartis Division Communications , World Health Organization , Global Head Of Drug Development , Novartis External Communications , Health Qual Life Outcomes , Exchange Commission , Canadian Drug Expert Committee Recommendation , National Eye Institute , National Health Insurance Pricing , European Society Of Retina Specialists , Canadian Agency For Drugs , Technologies In Health , Lancet Glob Health , Global Head ,

Novartis reports one year results of Phase III MERLIN study evaluating BEOVU® every four week dosing and provides update on BEOVU clinical program

/PRNewswire/ Today, Novartis reported the first interpretable year one results of the Phase III MERLIN study, a two-year study initiated in H2 2018,. ....

United States , United Kingdom , Lookeren Campagne , Beovu Basel , John Tsai , Health Qual Life Outcomes , National Eye Institute , National Health Insurance Pricing , Technologies In Health , World Health Organization , Global Head Of Drug Development , Canadian Drug Expert Committee Recommendation , Exchange Commission , Nj Novartis Pharmaceuticals Corporation , Novartis Pharmaceuticals Corporation , Canadian Agency For Drugs , European Society Of Retina Specialists , Lancet Glob Health , Global Head , Drug Development , Chief Medical Officer , North America , Age Related Macular Degeneration , Retinal Vascular , East Hanover , Pharmaceuticals Corporation ,